BlueRock’s allogeneic cell therapy approach is designed to address a number of important, difficult-to-treat conditions spanning neurodegeneration, cardiovascular disease and other areas of high patient need.
Our first therapeutic candidate, for Parkinson’s disease, is on track to enter the clinic in 2018. Parkinson’s is a chronic and progressive movement disorder that arises from the malfunction and death of vital nerve cells in the brain; it affects more than 6 million people worldwide. BlueRock’s approach is to restore natural dopamine production in the midbrain of Parkinson’s patients by replacing dopamine-secreting cells lost to degenerative disease.
Our second program will address heart failure, a leading cause of morbidity and mortality in more than 40 million people globally. Heart failure occurs when the heart can no longer pump sufficiently to maintain blood flow to meet the body’s needs. BlueRock’s cell therapy will remuscularize the heart by replacing the heart muscle cells lost after a heart attack.
BlueRock’s scientists and collaborators are world leaders in stem cell biology; the platform technology underlying our versatile approach hails from leading academic and medical institutions in the U.S., Canada and Japan.
Dr. Lorenz Studer, scientific co-founder of BlueRock Therapeutics and 2015 MacArthur Genius Award winner, and Dr. Viviane Tabar, neurosurgeon and founding investigator of BlueRock Therapeutics, are both with New York’s Memorial Sloan Kettering Cancer Center. Dr. Gordon Keller, a world leader in stem-cell biology and a scientific co-founder of BlueRock Therapeutics, and Dr. Michael A. Laflamme, a cardiac cell therapy pioneer and founding investigator of BlueRock Therapeutics, are based in Toronto at the McEwen Centre for Regenerative Medicine, University Health Network (UHN).
BlueRock also is collaborating with the licensing arm of Kyoto University and Dr. Shinya Yamanaka, a Nobel Prize winner for his cell reprogramming technology.
BlueRock-developed cardiomyocytes in an infarcted heart.
New York, NY
BlueRock is a fast-growing company acting on a mission to bring transformative treatments to patients in need. Our corporate culture is defined by a deep sense of urgency, married with the highest ethical standards and innovative technology.
Our team brings together diversity of thought and experience, with a shared mission to help all patients who could benefit from our novel cell therapy approach. We strive to be a top employer of scientific talent, empowering every member of the team to make meaningful and lasting contributions to the burgeoning field of regenerative medicine.
Over the next 12 months, BlueRock will be significantly expanding staff at all locations. Contact us to learn about our rewarding career opportunities in New York, Cambridge and Toronto.